BL-M11D1 vs PRGN-3006

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline

BL-M11D1

Developed by SystImmune

Phase 2/3 in Acute Myeloid Leukemiaantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05924750 (registry estimate)

No aligned efficacy figure on record for this race.

PRGN-3006

Developed by Precigen, Inc

Phase 1 in Acute Myeloid LeukemiaCAR-T cell therapy
Weak signal

NCT03927261 · Phase 1 · active, not recruiting

This trial enrolled all participants into a single treatment group with no randomization, no blinding, and no comparator arm, which is typical of an early Phase 1 safety study. Its primary goal was to check for dose-limiting toxicities rather than to statistically compare efficacy against a control, and an outside report notes no DLTs were seen, but because there was never a control group there is no formal test of a treatment effect to point to.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Number of Participants who Experience Dose Limiting Toxicities (DLTs) (Up to Day 42); Number of Participants who Experience Treatment Emergent Adverse Events (TEAEs) (Up to 12 months post treatment): PRGN-3006 (NCT03927261): no dose-limiting toxicities (DLTs) observed. (not_applicable)

Result source: NCT03927261

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBL-M11D1PRGN-3006
OS, median—Trial running · NCT07255872—Not reported
Complete remission—Trial running · NCT07255872—Not reported
Event-free survival, median—Trial running · NCT07255872—Not reported
Duration of response, median—Trial running · NCT07255872—Not reported

OS, median

BL-M11D1
—Trial running · NCT07255872
PRGN-3006
—Not reported

Complete remission

BL-M11D1
—Trial running · NCT07255872
PRGN-3006
—Not reported

Event-free survival, median

BL-M11D1
—Trial running · NCT07255872
PRGN-3006
—Not reported

Duration of response, median

BL-M11D1
—Trial running · NCT07255872
PRGN-3006
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BL-M11D1: no structured comparison results are available for Acute Myeloid Leukemia.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

PRGN-3006
PRGN-3006 (NCT03927261): no dose-limiting toxicities (DLTs) observed. NCT03927261 · Phase 1 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BL-M11D1's landscape · PRGN-3006's landscape